Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
Across cancer types, immune checkpoint inhibitors have been shown to induce complete
response, partial response, and stable disease after initial evidence of radiographic
increase in tumor burden. Treatment beyond progression should be considered when the patient
is stable (or improving) symptomatically and if tumor reassessment can be performed within a
short period.